Grissinger Michael 4

What Happened
Michael Grissinger, a director of Aprea Therapeutics (APRE), received equity awards on June 16, 2026 totaling 15,690 units: 3,135 shares granted as restricted stock units (RSUs) and 12,555 units reported as a derivative award. Both awards were granted at $0.00 (no cash paid) and have no immediate realized value at grant.

Key Details

• Transaction date: 2026-06-16; filing date: 2026-06-17 (timely filing).
• Grants: 3,135 RSUs @ $0.00; 12,555 derivative units @ $0.00. Total units granted = 15,690. Total immediate cash value = $0.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes:
  • F1: The 3,135 RSUs were granted 6/16/2026 and will vest and be settled in common stock on 6/16/2027, subject to continued board service and possible acceleration.
  • F2: The 12,555 derivative award vests in full on 6/16/2027, subject to continued board service and possible acceleration.
• Transaction type code: A (award/grant). Not a sale or open-market purchase.

Context
These awards are time-based grants that vest one year after the grant date if the director remains in service (with possible acceleration under certain conditions). Because they are not purchases or sales and have no immediate cash value, they do not directly signal buying or selling sentiment; they are standard compensation/retention awards for insiders.